The possible role of the ancillary properties of beta adrenoceptor antagonists in the management of angina pectoris.
Beta adrenoceptor antagonists are effective in the symptomatic management of angina pectoris. This paper examines critically the possible influence of the ancillary properties of beta 1 selectivity, partial agonism and membrane-stabilizing action on the response in anginal patients. The response is categorized according to experimental, pharmacological and clinical endpoints, placing emphasis on the possible errors which may arise from extrapolation from the former to the latter. It is concluded: That selective beta adrenoceptor antagonism confers limited, but tangible advantages over non-selective antagonists in regard to patients with reversible airways obstruction, and also in the metabolic and haemodynamic response to acute hypoglycaemia. Cardioselectivity does not influence the central haemodynamic response to exercise, but lessens adrenaline-mediated hypertensive responses to smoking and hypoglycaemia. Non-selective partial agonists cause less reduction in resting ventricular function, but their effects on cardiac output during exercise are indistinguishable from full antagonists. Membrane stabilizing properties have a marked influence on the tolerability of these agents in terms of unwanted, nonspecific central nervous system symptoms. Unresolved questions relate to the influence of partial agonism on fatigue, metabolic responses, especially blood lipids and glucose, and the possibility of lesser efficacy in angina compared to full antagonists.
Fitzgerald
J D
JD
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy; D001986:Bronchial Spasm / Q000139:chemically induced; D050260:Carbohydrate Metabolism; D002302:Cardiac Output / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects; D004285:Dogs; D004361:Drug Tolerance; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007741:Labetalol / Q000627:therapeutic use; D050356:Lipid Metabolism; D009129:Muscle Tonus / Q000187:drug effects; D009131:Muscle, Smooth, Vascular; D010101:Oxygen Consumption; D010869:Pindolol / Q000627:therapeutic use; D011217:Practolol / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D011506:Proteins / Q000378:metabolism; D014202:Tremor / Q000188:drug therapy; D014664:Vasodilation / Q000187:drug effects; D014693:Ventricular Fibrillation / Q000517:prevention & control
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D011506:Proteins; D010869:Pindolol; C024307:bucindolol; D007741:Labetalol; D011217:Practolol